NasdaqCM - Nasdaq Real Time Price USD

ProKidney Corp. (PROK)

Compare

0.7909

-0.0050

(-0.63%)

At close: April 17 at 4:00:01 PM EDT

0.8078

+0.02

+(2.14%)

After hours: April 17 at 7:36:39 PM EDT

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 22 days ago

PROK
-0.63%
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 28 days ago

PROK
-0.63%
ProKidney Reports Full Year 2024 Financial Results and Business Highlights

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-202

GlobeNewswire last month

PROK
-0.63%
Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK),

Key Insights Significantly high institutional ownership implies ProKidney's stock price is sensitive to their trading...

Simply Wall St. last month

PROK
-0.63%
US Penny Stocks: 3 Picks With Market Caps Under $300M

As U.S. markets recently took a pause from a rally, optimism around corporate earnings and AI development continues to shape investor sentiment. In this context, penny stocks—often smaller or newer companies—can present unique opportunities for investors looking beyond the major indices. Despite their vintage name, these stocks can offer surprising value when supported by solid financials and growth potential.

Simply Wall St. 2 months ago

PROK
-0.63%
EQC

PHLT
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare Conferen

GlobeNewswire 3 months ago

PROK
-0.63%
One ProKidney Insider Raised Their Stake In The Previous Year

Insiders were net buyers of ProKidney Corp.'s ( NASDAQ:PROK ) stock during the past year. That is, insiders bought more...

Simply Wall St. 3 months ago

PROK
-0.63%
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: Evercore HealthCONx ConferenceDate:December 3, 2024Time:8:45am ETFormat:Fireside ChatWebcast:Link Citi Global

GlobeNewswire 4 months ago

PROK
-0.63%
US Penny Stocks To Watch: 3 Picks With Market Caps Under $500M

As the U.S. stock market continues its rally, with the Dow Jones Industrial Average reaching record highs and the S&P 500 extending its winning streak, investors are increasingly exploring diverse opportunities across various sectors. Penny stocks, a term that may seem outdated but remains significant in investment circles, offer a unique blend of affordability and potential growth. Typically representing smaller or newer companies, these stocks can be attractive for those looking to uncover...

Simply Wall St. 4 months ago

PROK
-0.63%
BCOV

CTV
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed in that Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used Presented five posters at the ASN Kidney Week, including one late-breaking clinical trial and four posters on rilparencel’s product charact

GlobeNewswire 5 months ago

PROK
-0.63%
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November. Guggenheim Inaugural Healthcare Innovation Conference (Boston)Date:Wed, November 13, 2024Time:10:30am ETFormat:Fireside Chat

GlobeNewswire 5 months ago

PROK
-0.63%
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp

On August 28, 2024, Suvretta Capital Management, LLC, a prominent investment firm, executed a significant transaction by acquiring 3,857,500 shares of ProKidney Corp (NASDAQ:PROK). This move increased their total holdings in the company to 13,198,766 shares, marking a substantial investment in the biotechnology sector. The shares were purchased at a price of $2.21 each, reflecting a strategic addition to Suvretta's diverse portfolio.

GuruFocus.com 5 months ago

PROK
-0.63%
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 5 months ago

PROK
-0.63%
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024

WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA. The titles for the accepted abstracts are provided below

GlobeNewswire 6 months ago

PROK
-0.63%
ProKidney to Participate in the UBS Virtual Organ Restoration Day

WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024. UBS Virtual Organ Restoration DayDate: Tuesday, October 15, 2024Time: 9:00am ETFormat:

GlobeNewswire 6 months ago

PROK
-0.63%
ProKidney drops Phase III CKD study to focus on US market and save up to $175m

ProKidney is prioritising one of two clinical studies evaluating rilparencel, to bring the cell therapy to the US market quicker.

Clinical Trials Arena 7 months ago

PROK
-0.63%
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.

Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company’s highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development

GlobeNewswire 7 months ago

PROK
-0.63%
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024. Morgan Stanley 22nd Annual Global Healthcare Conferen

GlobeNewswire 7 months ago

PROK
-0.63%
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trialsClosed $140 million upsized underwritten public offering and concurrent registered direct offeringEnded the second quarter with $431.5 million in cash and cash equivalents and marketable securities, supporting operations through projected Phase 3 enrollment completion in mid-2026 WINS

GlobeNewswire 8 months ago

PROK
-0.63%
ProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutions

Key Insights Significant control over ProKidney by retail investors implies that the general public has more power to...

Simply Wall St. 8 months ago

PROK
-0.63%

Performance Overview

Return	PROK	S&P 500 (^GSPC)
YTD	-53.20%	-10.18%
1-Year	-72.15%	+5.19%
3-Year	-91.99%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ProKidney Corp. (PROK)

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK),

US Penny Stocks: 3 Picks With Market Caps Under $300M

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

One ProKidney Insider Raised Their Stake In The Previous Year

ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

US Penny Stocks To Watch: 3 Picks With Market Caps Under $500M

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

Suvretta Capital Management's Strategic Acquisition in ProKidney Corp

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024

ProKidney to Participate in the UBS Virtual Organ Restoration Day

ProKidney drops Phase III CKD study to focus on US market and save up to $175m

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

ProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutions

Performance Overview